BioSpace News Archive

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”) today announced its financial results for the three and nine months ended September 30, 2022, and highlighted recent events.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval for ELAHERE™ (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

Interpace Biosciences, Inc. announced financial results for the third quarter ended September 30, 2022 and provided a business and financial update.

Dewpoint Therapeutics Inc. announced the U.S. Patent and Trademark Office issued the patent “Methods of Characterizing Condensate-Associated Characteristics of Compounds and Uses Thereof” covering novel technology for partitioning and identifying compounds which preferentially partition into condensates of interest.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2022.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Edward C. Dow, who joined Oncternal as Vice President, Clinical Development.

RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has selected Recipharm, a leading Contract Development and Manufacturing Organization (CDMO).

Vancouver, British Columbia--(Newsfile Corp. - November 11, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), announces that it has entered into an assignment agreement with a certain arm’s length assignee (the “Assignee”).

Supporting the Company’s Suite of Compatible AOAC-Certified Assays, the Octa™AutoPrep Station Delivers 73% Lower Labor Costs, Up to 8x Less Consumable Waste

The global multiplex assays market size was USD 2.72 billion in 2020 and is expected to register a robust CAGR of 7.9% during the forecast period.